In vitro culture of isolated primary hepatocytes and stem cell-derived hepatocyte-like cells for liver regeneration.
10.1007/s13238-015-0180-2
- Author:
Chenxia HU
1
;
Lanjuan LI
Author Information
1. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, School of Medicine, First Affiliated Hospital, Zhejiang University, Hangzhou, 310006, China.
- Publication Type:Journal Article
- MeSH:
Cell Differentiation;
Embryonic Stem Cells;
cytology;
Hepatocytes;
cytology;
Humans;
Induced Pluripotent Stem Cells;
cytology;
Liver Regeneration;
Mesenchymal Stem Cells;
cytology;
Primary Cell Culture;
methods;
Regenerative Medicine;
methods;
Stem Cells;
cytology
- From:
Protein & Cell
2015;6(8):562-574
- CountryChina
- Language:English
-
Abstract:
Various liver diseases result in terminal hepatic failure, and liver transplantation, cell transplantation and artificial liver support systems are emerging as effective therapies for severe hepatic disease. However, all of these treatments are limited by organ or cell resources, so developing a sufficient number of functional hepatocytes for liver regeneration is a priority. Liver regeneration is a complex process regulated by growth factors (GFs), cytokines, transcription factors (TFs), hormones, oxidative stress products, metabolic networks, and microRNA. It is well-known that the function of isolated primary hepatocytes is hard to maintain; when cultured in vitro, these cells readily undergo dedifferentiation, causing them to lose hepatocyte function. For this reason, most studies focus on inducing stem cells, such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), hepatic progenitor cells (HPCs), and mesenchymal stem cells (MSCs), to differentiate into hepatocyte-like cells (HLCs) in vitro. In this review, we mainly focus on the nature of the liver regeneration process and discuss how to maintain and enhance in vitro hepatic function of isolated primary hepatocytes or stem cell-derived HLCs for liver regeneration. In this way, hepatocytes or HLCs may be applied for clinical use for the treatment of terminal liver diseases and may prolong the survival time of patients in the near future.
